News
NXT-2 Vaccine Process Development and Formulation Underway
The National Institute of Allergy and Infectious Diseases of the US National Institute of Health has awarded a contract for process development and formulation of the NXT-2 Pan Fungal Vaccine to begin in 2024. This is a critical milestone in the development of the NXT-2 vaccine for invasive fungal infections.
Preclinical studies show NXT-2 vaccine efficacy against Vulvovaginal Candida infection.
https://news.uga.edu/new-fungal-vaccine/ NXT-2 successfully protects against and treats vaginal yeast infections in mice, according to a newly published study.
This is the newest application of the vaccine, which was previously shown to protect against the three most common fungal pathogens in four preclinical animal models, including nonhuman primates. These three fungi are responsible for more than 80% of fatal fungal infections.
US Healthcare costs due to fungal infections top US $6B
https://scienmag.com/fungal-infections-cost-u-s-6-7b-in-a-year/
New research finds that fungal infections account for $6.7 billion in health care spending in the US 2018.
And that’s just the cases that were directly responsible for inpatient hospital stays.
Combined with secondary infections such as influenza and other clinical conditions, the total cost of hospital stays associated with fungal infections was in excess of $37.7 billion, comprising 1.1% of total U.S. national health care costs. This study used a pre-COVID hospitalization data set, and fungi-related costs are likely higher now, given the rise of secondary fungal infections in COVID-19 patients.